EGFR D770delinsGY

CI-VAR-00000550Explore in graph →ClinVar 177658 CIViC 2214

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR D770delinsGY	Erlotinib	Predictive	C	Supports Resistance	4	accepted	EID4801 In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progress… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
EGFR D770delinsGY	Erlotinib	Predictive	C	Supports Resistance	4	rejected	EID5942 2 patients with EGFR delD770insGY mutant lung adenocarcinoma were treated with first line erlotinib. A 76 year old female 6 pack year former smoker had progressive disease as best response with +38.1%… (full text at CIViC) PMID 24353160 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.